A study of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Tucidinostat (Primary) ; Busulfan; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Jan 2024 New trial record
- 12 Dec 2023 Results assessing safety and preliminary efficacy of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation presented at the 65th American Society of Hematology Annual Meeting and Exposition